Refine by
Drug Dose Articles & Analysis
18 news found
In today’s evolving pharmaceutical landscape, the search for new drug delivery systems (DDS) is of paramount importance to improving therapeutic outcomes. ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 60mcg dose for at-home use. This strategic trial design follows a Type B meeting with the U.S. Food and Drug Administration and observed dose-dependent responses in a prior Phase 1/2b study assessing a range of doses. ...
Therefore, it is an important target for the development of influenza drugs. Currently, the detection of neuraminidase and neuraminidase inhibitors (NIs) utilizing fluorescent neuraminidase assay is a major strategy in studying biological processes and preventing influenza infection. ...
All arms also received low doses of steroids as background therapy. Two hundred sixty-five patients were enrolled at centers in 20 countries worldwide. ...
All arms also received low doses of steroids as background therapy. 265 patients were enrolled at centers in 20 countries worldwide. ...
LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) with a dual mechanism of action, acting as an immunosuppressant through inhibition of T-cell activation and cytokine production and promoting podocyte stability in the kidney. The recommended starting dose of LUPKYNIS is three capsules twice daily with no requirement for serum drug monitoring. ...
Efficacy studies performed in a SUM-190PT breast cancer model of the Araris ADC demonstrated superior and complete tumor remission in all animals >100d even at 3x less drug dose applied vs EV. About Araris Biotech AG Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable ...
The poster presentation highlights the company’s anti-CD79b antibody-drug conjugate (ADC) and the oral presentation, taking place during the conference’s minisymposium, will highlight late-breaking data on a Nectin-4 ADC generated using the company’s proprietary linker technology. ...
Title: “Attainment of Complete Renal Response Results in Significant Improvements in Lupus Impact Tracker in the AURORA 1 Study of Voclosporin in Lupus Nephritis” Poster number: 319 Presenting author: Meenakshi Jolly, M.D., M.S., Associate Professor, Rush University, Chicago Title: “Confirmation of the Immunosuppressive Function of Voclosporin at the Clinically Relevant Lupus ...
“Furthermore, we observed that efficacy was maintained in combination with MMF and low-dose steroids.” Highlights of topline results from AURORA 2: In the 116 subjects in the voclosporin-treated group who enrolled in AURORA 2, mean estimated glomerular filtration rate (eGFR) was stable over 36 months. ...
Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with mycophenolate mofetil (MMF) at 1 g twice daily with either no or low-dose oral steroids, for an additional 24 months. A total of 216 LN ...
Nob Hill Therapeutics' Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonary Drug Delivery session on Friday, October 29th at 12:00pm ET. PODD is an annual virtual event where members of the pharma, biotech and drug delivery ...
This award is given to individuals who have made outstanding contributions to the field of Therapeutic Drug Monitoring (TDM). TDM is a field of medical science that seeks to ensure that patients receive a personalized dose of drugs to achieve an optimum therapeutic result. ...
The Latanoprost FA SR Ocular Implant is designed to provide a constant daily therapeutic dose of latanoprost free acid (the active ingredient of a commonly prescribed glaucoma eye-drop, Xalatan®) for 6-months. ...
Rahul Aggarwal as Principal Investigator, is a 30-40 patient dose escalation/expansion trial in men with advanced castration-resistant prostate cancer. The trial is designed to show safety and efficacy of CTT1403 and is halfway through the initial dose escalation phase. To date there have been no safety issues with the drug and the ...
The in silico platform reduces the cost and timeframe of drug development by reducing the need for iterative pre-clinical experiments and better directing clinical trials, while increasing the effectiveness of the therapeutics themselves. ...
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. ...